185 related articles for article (PubMed ID: 18600585)
1. AL-108 and AL-208, formulations of the neuroprotective NAP fragment of activity-dependent neuroprotective protein, for cognitive disorders.
Geerts H
Curr Opin Investig Drugs; 2008 Jul; 9(7):800-11. PubMed ID: 18600585
[TBL] [Abstract][Full Text] [Related]
2. Ispronicline (Targacept).
Geerts H
Curr Opin Investig Drugs; 2006 Jan; 7(1):60-9. PubMed ID: 16425673
[TBL] [Abstract][Full Text] [Related]
3. Microtubules, schizophrenia and cognitive behavior: preclinical development of davunetide (NAP) as a peptide-drug candidate.
Gozes I
Peptides; 2011 Feb; 32(2):428-31. PubMed ID: 21050875
[TBL] [Abstract][Full Text] [Related]
4. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model.
Vulih-Shultzman I; Pinhasov A; Mandel S; Grigoriadis N; Touloumi O; Pittel Z; Gozes I
J Pharmacol Exp Ther; 2007 Nov; 323(2):438-49. PubMed ID: 17720885
[TBL] [Abstract][Full Text] [Related]
5. NAP has no effect on spatial memory after short-term treatment in advanced stage Alzheimer's disease mouse model.
Van Dijck A; Van Dam D; De Deyn PP
Peptides; 2009 Dec; 30(12):2480-2. PubMed ID: 19664667
[TBL] [Abstract][Full Text] [Related]
6. Davunetide: a review of safety and efficacy data with a focus on neurodegenerative diseases.
Morimoto BH; Fox AW; Stewart AJ; Gold M
Expert Rev Clin Pharmacol; 2013 Sep; 6(5):483-502. PubMed ID: 23971871
[TBL] [Abstract][Full Text] [Related]
7. NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia.
Merenlender-Wagner A; Pikman R; Giladi E; Andrieux A; Gozes I
Peptides; 2010 Jul; 31(7):1368-73. PubMed ID: 20417241
[TBL] [Abstract][Full Text] [Related]
8. Gacyclidine (Beaufour-Ipsen).
Mitha AP; Maynard KI
Curr Opin Investig Drugs; 2001 Jun; 2(6):814-9. PubMed ID: 11572662
[TBL] [Abstract][Full Text] [Related]
9. BMS-204352 (Bristol Myers Squibb).
Mackay KB
Curr Opin Investig Drugs; 2001 Jun; 2(6):820-3. PubMed ID: 11572663
[TBL] [Abstract][Full Text] [Related]
10. NNZ-2566: a Gly-Pro-Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke.
Bickerdike MJ; Thomas GB; Batchelor DC; Sirimanne ES; Leong W; Lin H; Sieg F; Wen J; Brimble MA; Harris PW; Gluckman PD
J Neurol Sci; 2009 Mar; 278(1-2):85-90. PubMed ID: 19157421
[TBL] [Abstract][Full Text] [Related]
11. CEP-1347 (Cephalon).
Mucke HA
IDrugs; 2003 Apr; 6(4):377-83. PubMed ID: 12789610
[No Abstract] [Full Text] [Related]
12. Rivastigmine in Parkinson's disease dementia.
Chitnis S; Rao J
Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):941-55. PubMed ID: 19619073
[TBL] [Abstract][Full Text] [Related]
13. DP-b99 (D-Pharm).
Yeung PK
Curr Opin Investig Drugs; 2004 Jan; 5(1):90-4. PubMed ID: 14983980
[TBL] [Abstract][Full Text] [Related]
14. Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP).
Magen I; Gozes I
Neuropeptides; 2013 Dec; 47(6):489-95. PubMed ID: 24210139
[TBL] [Abstract][Full Text] [Related]
15. The microtubule interacting drug candidate NAP protects against kainic acid toxicity in a rat model of epilepsy.
Zemlyak I; Manley N; Vulih-Shultzman I; Cutler AB; Graber K; Sapolsky RM; Gozes I
J Neurochem; 2009 Dec; 111(5):1252-63. PubMed ID: 19799711
[TBL] [Abstract][Full Text] [Related]
16. [A hormonal drug melatonin in the treatment of cognitive function disorders in parkinsonism].
Arushanian EB
Eksp Klin Farmakol; 2010 Mar; 73(3):35-9. PubMed ID: 20408429
[TBL] [Abstract][Full Text] [Related]
17. Nicaraven Chugai.
Leker RR
Curr Opin Investig Drugs; 2003 Jan; 4(1):83-90. PubMed ID: 12625035
[TBL] [Abstract][Full Text] [Related]
18. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP).
Gozes I; Morimoto BH; Tiong J; Fox A; Sutherland K; Dangoor D; Holser-Cochav M; Vered K; Newton P; Aisen PS; Matsuoka Y; van Dyck CH; Thal L
CNS Drug Rev; 2005; 11(4):353-68. PubMed ID: 16614735
[TBL] [Abstract][Full Text] [Related]
19. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
[TBL] [Abstract][Full Text] [Related]
20. Clinical trials in neuroprotection.
Whitcup SM
Prog Brain Res; 2008; 173():323-35. PubMed ID: 18929119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
